Ralpancizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ralpancizumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetneural apoptosis-regulated proteinase 1
Clinical data
Other namesRN317
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6422H9922N1730O2012S54
Molar mass145.3 kg/mol g·mol−1

Ralpancizumab (INN;[1] development code RN317) is a monoclonal antibody designed for the treatment of dyslipidemia.[2]

This drug was developed by Pfizer.

References[edit]

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ralpancizumab, American Medical Association.